The Effect of Carvedilol VS Endoscopic Therapy in Primary Prophylaxis of High-risk Esophageal Gastric Variceal Bleeding

• Status: Unknown status
• Trial end date: 2018-09-01
• Target enrollment: 0
• Participant gender: All

Summary

To compare the efficacy and safety of Carvedilol and endoscopic therapy in Primary Prophylaxis of High-risk Esophageal Gastric Variceal Bleeding.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Shanghai Zhongshan Hospital
• Collaborators: Eastern Hepatobiliary Surgery Hospital; Gongli Hospital, School of Medicine, The Second Military Medical University; Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine; Shanghai Public Health Clinical Center; ShuGuang Hospital; Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
• Treatments: Carvedilol

Criteria

Inclusion Criteria:

• the presence of severe esophageal and gastric varices at upper gastrointestinal endoscopy without a previous haemorrhage

• a diagnosis of liver cirrhosis based on histology, clinical or imaging manifestation

Exclusion Criteria:

• age greater than 80 years old or younger than 18 years old

• non-cirrhotic portal hypertension

• contraindications to NSBB including bronchospasm, severe bradycardia, severe heart failure, acute pulmonary edema, atrioventricular block and so on

• ABPsys less than 95 mmHg or HR less than 50 bpm

• prior treatment for prevention of bleeding from EGV

• presence of spontaneous bacterial peritonitis or other severe infections

• presence of hepatorenal syndrome

• uncontrolled hepatic encephalopathy

• presence of refractory ascites

• pregnancy

• presence of portosystemic shunt or portal cavernous transformation

• refusal to participate in the study